Clinical Trial: ALLIANCE A011801

ALLIANCE A011801

Status: Open

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Eligible for screening study DCP 001

A011801, H01 Quality of Life Substudy, is closed to new patient enrollment effective July 22, 2024.